CAS 2432994-31-3

N-[3-(Difluoromethyl)-1-[trans-4-[[4-[[3-[1-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-4-yl]-2-propyn-1-yl]oxy]-1-piperidinyl]methyl]cyclohexyl]-1H-pyrazol-4-yl]-5-(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide

CAS: 2432994-31-3

Fórmula: C₄₄H₄₉F₂N₁₁O₆

Pureza: 98%

Forma y color: Solid

Peso molecular: 865.9268

Ref: IN-DA024RWC

KT-474

CAS: 2432994-31-3

KT-474

Pureza: ≥98%

Peso molecular: 865.93g/mol

Ref: 54-BUP21029

KT-474

CAS: 2432994-31-3

KT-474

Pureza: 98%

Ref: 54-BI12232

KT-474

CAS: 2432994-31-3

KT-474 (KYM-001) is a PROTAC degrader targeting IRAK4 with antitumor activity for the study of autoimmune diseases.

Fórmula: C₄₄H₄₉F₂N₁₁O₆

Pureza: 98.50% - 99.57%

Forma y color: Solid

Peso molecular: 865.93

Ref: TM-T74411

KT-474

CAS: 2432994-31-3

KT-474 is an oral small molecule protein degrader, which is derived from targeted protein degradation technology. This compound functions as an investigational agent specifically designed to degrade IRAK4, a key kinase involved in the signaling pathways of pro-inflammatory cytokines such as IL-1 and IL-18, which are crucial in the regulation of innate and adaptive immunity. The mode of action is based on hijacking the cell's ubiquitin-proteasome system to selectively bind to and degrade IRAK4, thereby reducing inflammation at the molecular level.

Fórmula: C₄₄H₄₉F₂N₁₁O₆

Pureza: Min. 95%

Peso molecular: 865.93 g/mol

Ref: 3D-BK184142